These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16647934)

  • 1. Sex hormone-binding globulin--a surrogate marker for the prothrombic effects of combined oral contraceptives.
    van Rooijen M; Silveira A; Hamsten A; Bremme K
    Am J Obstet Gynecol; 2006 May; 194(5):1499. PubMed ID: 16647934
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of ethinylestradiol dose and progestagen in combined oral contraceptives on plasma sex hormone-binding globulin levels in premenopausal women.
    Stegeman BH; Raps M; Helmerhorst FM; Vos HL; van Vliet HA; Rosendaal FR; van Hylckama Vlieg A
    J Thromb Haemost; 2013 Jan; 11(1):203-5. PubMed ID: 23122048
    [No Abstract]   [Full Text] [Related]  

  • 3. Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives.
    Raps M; Helmerhorst F; Fleischer K; Thomassen S; Rosendaal F; Rosing J; Ballieux B; VAN Vliet H
    J Thromb Haemost; 2012 Jun; 10(6):992-7. PubMed ID: 22469296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?
    Odlind V; Milsom I; Persson I; Victor A
    Acta Obstet Gynecol Scand; 2002 Jun; 81(6):482-90. PubMed ID: 12047300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex hormone-binding globulin: not a surrogate marker for venous thromboembolism in women using oral contraceptives.
    Stanczyk FZ; Grimes DA
    Contraception; 2008 Sep; 78(3):201-3. PubMed ID: 18692609
    [No Abstract]   [Full Text] [Related]  

  • 6. Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens.
    van Vliet HA; Frolich M; Christella M; Thomassen LG; Doggen CJ; Rosendaal FR; Rosing J; Helmerhorst FM
    Hum Reprod; 2005 Feb; 20(2):563-8. PubMed ID: 15539435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex hormone--binding globulin--a surrogate marker for the prothrombotic effects of combined oral contraceptives.
    van Rooijen M; Silveira A; Hamsten A; Bremme K
    Am J Obstet Gynecol; 2004 Feb; 190(2):332-7. PubMed ID: 14981370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex hormone-binding globulin: an adequate surrogate marker for venous thromboembolism in women using new hormonal contraceptives.
    van Vliet HA; Rosendaal FR; Rosing J; Helmerhorst FM
    Contraception; 2009 Apr; 79(4):328-9; author reply 329-30. PubMed ID: 19272504
    [No Abstract]   [Full Text] [Related]  

  • 9. Determining the time androgens and sex hormone-binding globulin take to return to baseline after discontinuation of oral contraceptives in women with polycystic ovary syndrome: a prospective study.
    Sánchez LA; Pérez M; Centeno I; David M; Kahi D; Gutierrez E
    Fertil Steril; 2007 Mar; 87(3):712-4. PubMed ID: 17118366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study.
    Fleischer K; van Vliet HA; Rosendaal FR; Rosing J; Tchaikovski S; Helmerhorst FM
    Thromb Res; 2009; 123(3):429-35. PubMed ID: 18829069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of venous thromboembolism in users of combined oral contraceptives. Risk is particularly high with first use of oral contraceptives.
    Vandenbrouke JP; Bloemenkamp KW; Rosendaal FR; Helmerhorst FM
    BMJ; 2000 Jan; 320(7226):57-8. PubMed ID: 10671043
    [No Abstract]   [Full Text] [Related]  

  • 12. [Third generation oral contraceptives and risk of venous thrombosis--the English lesson].
    Sørensen MB
    Ugeskr Laeger; 2002 Apr; 164(18):2418; author reply 2418-9. PubMed ID: 12024851
    [No Abstract]   [Full Text] [Related]  

  • 13. Sex hormones and thrombosis.
    Watson HG
    Semin Hematol; 2007 Apr; 44(2):98-105. PubMed ID: 17433902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Marvelon--when the adverse effects become a marketing argument].
    Hansson V
    Tidsskr Nor Laegeforen; 1986 Apr; 106(11):966-8. PubMed ID: 2941893
    [No Abstract]   [Full Text] [Related]  

  • 15. Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives: a rebuttal.
    Kluft C; Skouby SO; Jespersen J; Burggraaf J
    J Thromb Haemost; 2013 Feb; 11(2):394-5. PubMed ID: 23140257
    [No Abstract]   [Full Text] [Related]  

  • 16. Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives: reply to a rebuttal.
    Raps M; Helmerhorst FM; Fleischer K; van Hylckama Vlieg A; Stegeman BH; Thomassen S; Rosendaal FR; Rosing J; Ballieux BE; Van Vliet HA
    J Thromb Haemost; 2013 Feb; 11(2):396-7. PubMed ID: 23176323
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral contraceptives and venous thromboembolic events.
    Shulman LP; Goldzieher JW; Minkin MJ; Sulak PJ; Thorneycroft I
    J Reprod Med; 2003 Apr; 48(4):306-7. PubMed ID: 12747000
    [No Abstract]   [Full Text] [Related]  

  • 18. Incidence of venous thromboembolism in users of combined oral contraceptives. Methods for identifying cases and estimating person time at risk must be detailed.
    Jick H
    BMJ; 2000 Jan; 320(7226):57; author reply 57-8. PubMed ID: 10617543
    [No Abstract]   [Full Text] [Related]  

  • 19. Drospirenone: venous thrombosis (continued).
    Prescrire Int; 2012 Feb; 21(124):43. PubMed ID: 22413722
    [No Abstract]   [Full Text] [Related]  

  • 20. [Changes in haemostasis by the use of oral contraceptives].
    Uchikova E; Milchev N; Markova D; Gŭrova A; Batashki I
    Akush Ginekol (Sofiia); 2007; 46(1):24-7. PubMed ID: 17469458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.